The Relationship Between Gait Task Performance and Plasma Biomarkers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults and Patients with Mild Cognitive Impairment
Authors:
- Jordan SergioJSJordan Sergio
- Ashley PriceAPAshley Price
- Peter SnyderPSPeter Snyder
- Savannah DosterSDSavannah Doster
- Maeve DurkinMDMaeve Durkin
- Jennifer StrengerJSJennifer Strenger
- Louisa ThompsonLTLouisa Thompson
- Megan StradtmanMSMegan Stradtman
- Stuart SinoffSSStuart Sinoff
- Jessica AlberJAJessica Alber
Open Access
- 1 February 2026
- journal article
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 21, 1-13
Abstract
The Timed Up and Go (TUG) is a 20-foot gait assessment, with TUG-dual task (DT) serial subtractions to determine dual-task cost. Alzheimer’s disease (AD) risk is established using plasma biomarkers and APOE genotyping. We investigated: 1) TUG/TUG-DT differences between AD low-risk cognitively unimpaired (CU) older adults (N = 74), AD high-risk CU older adults (N = 87), and mild cognitively impaired (MCI) older adults (N = 33) and 2) the relationship between TUG/TUG-DT performance and plasma biomarkers. One hundred and ninety-four older adults ages 55–80 completed TUG/TUG-DT, a fasting blood draw, and APOE genotyping. Scores on the Clinical Dementia Rating Scale (CU = 0; CI = ≥0.5) and Montreal Cognitive Assessment (CU ≥ 24; CI = ≤23) determined whether participants were placed into the CU low-risk, CU high-risk, or MCI groups. Risk level for CU participants were assessed by APOE genotyping. Those participants who carried at least one copy of the APOE ε4 allele were designated to the high-risk group (n = 87). Participants with no APOE ε4 allele were assigned to the low-risk group (n = 75). MCI participants took longer to perform the TUG than CU participants (p < 0.001). CU high-risk and MCI group performed similarly on step counts, while the CU low-risk took significantly fewer steps (p<0.001). Speed predicted whether someone was below an AD-risk threshold for pTau217 in CU participants (n = 150). Exploratory generalized additive models showed plasma biomarkers predicted gait metrics in CU groups. Step count may be more sensitive, compared to speed alone, in identifying those in preclinical AD stages. Gait metrics (speed and efficiency) played a key role as a clinical manifestation of early AD pathophysiology determined by blood-based biomarker concentration. Combining these assessments offers a multidimensional, cost-effective approach for preclinical-AD screening and potential early intervention.Keywords
This publication has 38 references indexed in Scilit:
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE studyAlzheimer's & Dementia, 2021
- Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forwardAlzheimer's & Dementia, 2020
- Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer DiseaseJAMA Neurology, 2017
- Association of Dual-Task Gait With Incident Dementia in Mild Cognitive ImpairmentJAMA Neurology, 2017
- The Trajectory of Gait Speed Preceding Mild Cognitive ImpairmentArchives of Neurology, 2010
- Motor Dysfunction in Mild Cognitive Impairment and the Risk of Incident Alzheimer DiseaseArchives of Neurology, 2006
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997